Landos Biopharma secures $60M Series B round for IBD treatment

Landos Biopharma has completed a $60 million Series B round.

“I am delighted to announce the closing of a $60 million Series B financing,” Josep Bassaganya-Riera, DVM, PhD, president and CEO of Landos, said in a press release. “This financing is an important part of our strategy to advance lead product BT-11 into global phase 2 clinical trials for ulcerative colitis and Crohn’s disease. There is an unmet clinical need for new therapies for complex diseases such as inflammatory bowel disease.”

Landos expects the funding to support its phase 2 global clinical trials for BT-11 in ulcerative colitis and Crohn’s disease.

BT-11 targets the gastrointestinal tract through the Lanthionine Synthetase C-Like 2 (LANCL2) pathway and helps create a favorable regulatory microenvironment in the gut, according to the release.

In May, data published in IBD Journal demonstrated that BT-11 was well-tolerated in patients and fecal calprotectin levels were lower in patients who received BT-11 compared with those who received placebo.

Landos Biopharma has completed a $60 million Series B round.

“I am delighted to announce the closing of a $60 million Series B financing,” Josep Bassaganya-Riera, DVM, PhD, president and CEO of Landos, said in a press release. “This financing is an important part of our strategy to advance lead product BT-11 into global phase 2 clinical trials for ulcerative colitis and Crohn’s disease. There is an unmet clinical need for new therapies for complex diseases such as inflammatory bowel disease.”

Landos expects the funding to support its phase 2 global clinical trials for BT-11 in ulcerative colitis and Crohn’s disease.

BT-11 targets the gastrointestinal tract through the Lanthionine Synthetase C-Like 2 (LANCL2) pathway and helps create a favorable regulatory microenvironment in the gut, according to the release.

In May, data published in IBD Journal demonstrated that BT-11 was well-tolerated in patients and fecal calprotectin levels were lower in patients who received BT-11 compared with those who received placebo.

    See more from Ulcerative Colitis Resource Center